Clinical Trials

Other hematologic neoplasm

317 enrolled

GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Neoplasm Metastasis

NCT03486873 2026-03-16

MK-3475-587

Phase 3 Recruiting

3,500 enrolled

Hematologic Neoplasms

NCT04164199 2026-03-16

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Phase 3 Enrolling by invitation

430 enrolled

Advanced Malignancies

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

BreastGynecologicThoracic

182 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05523323 2026-03-13

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension

112 enrolled 16 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03573960 2026-03-06

A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer

Phase 4 Completed

50 enrolled

Head & Neck

Thyroid Neoplasms

NCT05319730 2026-03-02

MK-3475-06B

230 enrolled

Phase 1/2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT04008797 2026-02-27

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

301 enrolled

GastrointestinalGynecologic

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT02811861 2026-02-23

CLEAR

Phase 3 Active not recruiting

1,069 enrolled 12 charts 1 FDA

Carcinoma, Renal Cell

NCT03829332 2026-02-19

LEAP-007

Phase 3 Active not recruiting

623 enrolled 26 charts

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04039607 2026-02-19

CheckMate 9DW

732 enrolled 1 FDA

Carcinoma, Hepatocellular

NCT05775159 2026-02-18

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Phase 2 Recruiting

294 enrolled

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT02861573 2026-02-17

KEYNOTE-365

1,200 enrolled

Phase 1/2 Active not recruiting

Metastatic Castration-Resistant Prostate Cancer

NCT04626479 2026-02-12

MK-3475-03A

400 enrolled

Phase 3 Not yet recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT07405164 2026-02-12

MK-6482-043

450 enrolled

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT03820986 2026-02-09

LEAP-003

674 enrolled 21 charts

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT03713593 2026-02-05

LEAP-002

794 enrolled 30 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

NCT03829319 2026-02-05

LEAP-006

761 enrolled 31 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03898180 2026-02-05

LEAP-011

505 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT04776148 2026-02-05

MK-7902-017

563 enrolled 32 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT03884101 2026-02-02

LEAP-001

Phase 1 Active not recruiting

842 enrolled 25 charts

Gynecologic

Endometrial Neoplasms

NCT05081180 2026-01-23

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

17 enrolled

CNS

Neoplasms, Central Nervous System Neoplasms

NCT07081633 2025-12-30

TREMENDOUS-2

Phase 2 Recruiting

114 enrolled

Carcinoma, Hepatocellular

NCT04889118 2025-12-23

LEAP-003